153 related articles for article (PubMed ID: 15465155)
1. Comment on: 'Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients' Radiother Oncol 70: 261-264, 2004 by Dr Rades et al.
Cengiz M; Onal C; Yildiz F; Zorlu AF
Radiother Oncol; 2004 Oct; 73(1):109; author reply 109-10. PubMed ID: 15465155
[No Abstract] [Full Text] [Related]
2. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.
Rades D; Fehlauer F; Bajrovic A; Mahlmann B; Richter E; Alberti W
Radiother Oncol; 2004 Mar; 70(3):261-4. PubMed ID: 15064010
[TBL] [Abstract][Full Text] [Related]
3. Stevens-Johnson syndrome and toxic epidermal necrolysis induced by amifostine during head and neck radiotherapy.
Valeyrie-Allanore L; Poulalhon N; Fagot JP; Sekula P; Davidovici B; Sidoroff A; Mockenhaupt M
Radiother Oncol; 2008 May; 87(2):300-3. PubMed ID: 18328585
[TBL] [Abstract][Full Text] [Related]
4. A new administration schedule for amifostine as a radioprotector in cancer therapy.
Wagner W; Radmard A; Schönekaes KG
Anticancer Res; 1999; 19(3B):2281-3. PubMed ID: 10472344
[TBL] [Abstract][Full Text] [Related]
5. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
Thorstad WL; Chao KS; Haughey B
Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
[TBL] [Abstract][Full Text] [Related]
6. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
Buentzel J; Micke O; Adamietz IA; Monnier A; Glatzel M; de Vries A
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):684-91. PubMed ID: 16243440
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
Law A; Kennedy T; Pellitteri P; Wood C; Christie D; Yumen O
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1361-8. PubMed ID: 17869022
[TBL] [Abstract][Full Text] [Related]
8. Amifostine as a radioprotectant.
Gosselin TK; Mautner B
Clin J Oncol Nurs; 2002; 6(3):175-6, 180. PubMed ID: 11998614
[No Abstract] [Full Text] [Related]
9. In regard to Boccia et al.: assessment and management of cutaneous reactions with amifostine administration: findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP) (INT J RADIAT ONCOL BIOL PHYS 2004;60:302-309).
Hicsonmez A; Andrieu MN; Akyurek S; Karaca M; Cagar A; Ciner F; Kurtman C
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1279; author reply 1279. PubMed ID: 15752917
[No Abstract] [Full Text] [Related]
10. [New data on cytoprotection in radiotherapy].
Sauer R; Strnad V
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():1. PubMed ID: 10584131
[No Abstract] [Full Text] [Related]
11. [Radioprotective effects on head and neck tumors of amifostine--a broad-spectrum cytoprotection].
Huang R; Yu H; Kuang A
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2002 Dec; 19(4):708-11. PubMed ID: 12561384
[TBL] [Abstract][Full Text] [Related]
12. Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients.
de Castro G; Federico MH
Curr Opin Oncol; 2006 May; 18(3):266-70. PubMed ID: 16552239
[TBL] [Abstract][Full Text] [Related]
13. Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function.
Veerasarn V; Phromratanapongse P; Suntornpong N; Lorvidhaya V; Sukthomya V; Chitapanarux I; Tesavibul C; Swangsilpa T; Khorprasert C; Shotelersuk K; Kongthanarat Y; Panichevaluk A; Chiewvit S; Pusuwan P; Aekmahachai M; Ratchadara S; Sirilipoche S; Saengsuda Y
J Med Assoc Thai; 2006 Dec; 89(12):2056-67. PubMed ID: 17214057
[TBL] [Abstract][Full Text] [Related]
14. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
Ozsahin M; Betz M; Matzinger O; Bron L; Luthi F; Pasche P; Azria D; Mirimanoff RO; Zouhair A
Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870
[TBL] [Abstract][Full Text] [Related]
15. Amifostine reduces radiation therapy-induced dry mouth in head and neck cancer patients.
Oncology (Williston Park); 2004 Sep; 18(10):1314, 1316. PubMed ID: 15526835
[No Abstract] [Full Text] [Related]
16. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
[TBL] [Abstract][Full Text] [Related]
17. Amifostine enhances recovery and expansion of peripheral FAS/CD95+ T- and NK-cell subpopulations during radiotherapy of patients with head-neck cancer.
Koukourakis GV; Baksevanis CN; Zambatis H; Gritzapis A; Maltezos E; Simopoulos C; Koukourakis MI
Int J Radiat Biol; 2009 Jan; 85(1):96-104. PubMed ID: 19205988
[TBL] [Abstract][Full Text] [Related]
18. Daily subcutaneous amifostine administration during irradiation of pediatric head and neck cancers.
Anacak Y; Kamer S; Haydaroglu A
Pediatr Blood Cancer; 2007 May; 48(5):579-81. PubMed ID: 16395679
[TBL] [Abstract][Full Text] [Related]
19. Two cases of Stevens-Johnson syndrome: toxic epidermal necrolysis possibly induced by amifostine during radiotherapy.
Lale Atahan I; Ozyar E; Sahin S; Yildiz F; Yalçin B; Karaduman A
Br J Dermatol; 2000 Nov; 143(5):1072-3. PubMed ID: 11069524
[No Abstract] [Full Text] [Related]
20. A randomized phase II trial of amifostine for head and neck irradiation in lymphoma.
Ng AK; Hickey G; Li S; Neuberg D; Mauch PM
Semin Oncol; 2004 Dec; 31(6 Suppl 18):20-4. PubMed ID: 15726518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
